Comparison of intensity modulated radiotherapy with simultaneous integrated boost (IMRT-SIB) and a 3-dimensional conformal parotid gland-sparing radiotherapy (ConPas 3D-CRT) in treatment of nasopharyngeal carcinoma: a mono-institutional experience
- 61 Downloads
To compare intensity modulated radiotherapy with simultaneous integrated boost (IMRT-SIB) and a 3-dimensional conformal parotid gland-sparing radiotherapy (ConPas 3D-CRT) in treatment of nasopharyngeal carcinoma with regard to outcomes and dose distribution to the planning target volumes (PTVs) and to the organs at risk (OARs).
The treatment records of 24 patients with histologically proven carcinoma of the nasopharynx treated with ConPas 3D-CRT or IMRT-SIB technique between May 2009 and December 2016 were assessed.
The mean dose and dose to 50% parotid glands volume as well as the maximal dose to the spinal cord were significantly lower in the IMRT-SIB than in the ConPas 3-CRT group (p < 0.05; p < 0.05; p < 0.01, respectively). IMRT-SIB was also superior in coverage of PTVs. The 3-year overall survival (OS) and disease-free survival (DFS) of patients in the IMRT-SIB and ConPas 3D-CRT groups were 77 and 81% (p = 0.93), 51.9 and 70.7% (p = 0.83), respectively.
IMRT-SIB provided additional spearing to parotid glands and spinal cord in comparison to ConPas 3D-CRT technique but without improvement of OS and DFS.
KeywordsNasopharyngeal cancer Radiotherapy Treatment techniques Organs at risk
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedure performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the Ethics Committee of the University Hospital Zagreb.
Informed consent was obtained from all individual participants included in the study.
- 1.Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C et al (2013) GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11. Lyon, France: International Agency for Research on Cancer. http://globocan.iarc.fr. Accessed 6 May 2017
- 5.Peng G, Wang T, Yang KY, Zhang S, Zhang T, Li Q et al (2012) A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. Radiother Oncol 104:286–293CrossRefPubMedGoogle Scholar
- 8.Pow EH, Kwong DL, McMillan AS, Wong MC, Sham JS, Leung LH et al (2006) Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys 66:981–991CrossRefPubMedGoogle Scholar
- 11.Fang FM, Chien CY, Tsai WL, Chen HC, Hsu HC, Lui CC et al (2008) Quality of life and survival outcome for patients with nasopharyngeal carcinoma receiving three-dimensional conformal radiotherapy vs. intensity-modulated radiotherapy—a longitudinal study. Int J Radiat Oncol Biol Phys 72:356–364CrossRefPubMedGoogle Scholar
- 16.ICRU (2010) Report no 83. Prescribing, recording and reporting photon-beam intensity-modulated radiation therapy (IMRT). J ICRU 10:1473–6691Google Scholar
- 24.R Core Team (2008) R: A language and environment for statistical computing. R Foundation for statistical computing, Vienna, FranceGoogle Scholar
- 25.Therneau T (2015) A Package for Survival Analysis in S. Version 2.38. https://CRAN.Rproject.org/package=survival. Accessed 13 Apr 2017
- 26.Kassambara A, Kosinski M (2017) Survimner: drawing survival curves using “ggplot2”. R package version 0.3.1Google Scholar
- 35.Yao JJ, Chen FP, Zhou GQ, Zhang WJ, Xu L, Wang XJ et al (2016) A prospective study on radiation doses to organs at risk (OARs) during intensity-modulated radiotherapy for nasopharyngeal carcinoma patients. Oncotarget 7:2142–2152Google Scholar
- 37.Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C et al (2011) Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 12(2):127–136CrossRefPubMedPubMedCentralGoogle Scholar